Cargando…

The complexities of insulin allergy: a case and approach

BACKGROUND: Insulin hypersensitivity is rare, but challenging for individuals with diabetes. The prevalence of insulin allergy has decreased since the introduction of human recombinant insulin preparations. Hypersensitivity reactions range from injection site erythema and swelling, to anaphylaxis. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Aberumand, Babak, Jeimy, Samira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320219/
https://www.ncbi.nlm.nih.gov/pubmed/34325725
http://dx.doi.org/10.1186/s13223-021-00554-1
_version_ 1783730606622900224
author Aberumand, Babak
Jeimy, Samira
author_facet Aberumand, Babak
Jeimy, Samira
author_sort Aberumand, Babak
collection PubMed
description BACKGROUND: Insulin hypersensitivity is rare, but challenging for individuals with diabetes. The prevalence of insulin allergy has decreased since the introduction of human recombinant insulin preparations. Hypersensitivity reactions range from injection site erythema and swelling, to anaphylaxis. While some reactions are to excipients (zinc, protamine, metacresol), many are to recombinant insulin itself. We present a case of type 1 hypersensitivity to various preparations of insulin in a patient with insulin-dependent type 2 diabetes mellitus (T2DM). CASE PRESENTATION: A 61-year-old woman with a 30-year history of insulin-dependent T2DM was referred for evaluation of reactions to insulin. She had two episodes over 5-months; both required Emergency Department visits and epinephrine administration. The first episode entailed a burning sensation of the extremities and nausea, immediately after injecting NovoRapid(®) insulin. The second event entailed a similar reaction but this time there was also angioedema of the upper airway with difficulty breathing and hypotension, immediately after injecting Levemir(®) and NovoRapid(®), and taking metformin. There were no cofactors such as exercise, infectious illness, or NSAIDs use. Skin testing was performed with metformin, Lantus(®), Humalog(®), NovoRapid(®), glulisine, insulin regular, NPH, Levemir(®) and the excipient protamine, as per published testing concentrations. Metacresol was not tested as its use was restricted by the hospital pharmacy. Insulin preparations with and without metacresol were included in testing however. A clinic staff served as a negative control. The patent had negative testing with protamine, but sensitization to all insulin preparations. Metformin skin testing and challenge along with latex IgE were negative. Subsequently, she underwent intentional weight loss of 70 lb, and was started on oral hypoglycemics with good effect. CONCLUSIONS: Our case highlights the importance of diagnosing insulin allergy through a detailed history and focused testing. Therapeutic strategies include avoidance and insulin alternatives, alternate insulin preparations, or desensitization. In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective.
format Online
Article
Text
id pubmed-8320219
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83202192021-07-30 The complexities of insulin allergy: a case and approach Aberumand, Babak Jeimy, Samira Allergy Asthma Clin Immunol Case Report BACKGROUND: Insulin hypersensitivity is rare, but challenging for individuals with diabetes. The prevalence of insulin allergy has decreased since the introduction of human recombinant insulin preparations. Hypersensitivity reactions range from injection site erythema and swelling, to anaphylaxis. While some reactions are to excipients (zinc, protamine, metacresol), many are to recombinant insulin itself. We present a case of type 1 hypersensitivity to various preparations of insulin in a patient with insulin-dependent type 2 diabetes mellitus (T2DM). CASE PRESENTATION: A 61-year-old woman with a 30-year history of insulin-dependent T2DM was referred for evaluation of reactions to insulin. She had two episodes over 5-months; both required Emergency Department visits and epinephrine administration. The first episode entailed a burning sensation of the extremities and nausea, immediately after injecting NovoRapid(®) insulin. The second event entailed a similar reaction but this time there was also angioedema of the upper airway with difficulty breathing and hypotension, immediately after injecting Levemir(®) and NovoRapid(®), and taking metformin. There were no cofactors such as exercise, infectious illness, or NSAIDs use. Skin testing was performed with metformin, Lantus(®), Humalog(®), NovoRapid(®), glulisine, insulin regular, NPH, Levemir(®) and the excipient protamine, as per published testing concentrations. Metacresol was not tested as its use was restricted by the hospital pharmacy. Insulin preparations with and without metacresol were included in testing however. A clinic staff served as a negative control. The patent had negative testing with protamine, but sensitization to all insulin preparations. Metformin skin testing and challenge along with latex IgE were negative. Subsequently, she underwent intentional weight loss of 70 lb, and was started on oral hypoglycemics with good effect. CONCLUSIONS: Our case highlights the importance of diagnosing insulin allergy through a detailed history and focused testing. Therapeutic strategies include avoidance and insulin alternatives, alternate insulin preparations, or desensitization. In severe recurrent hypersensitivity reactions, Omalizumab or pancreatic transplantation have been effective. BioMed Central 2021-07-29 /pmc/articles/PMC8320219/ /pubmed/34325725 http://dx.doi.org/10.1186/s13223-021-00554-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Aberumand, Babak
Jeimy, Samira
The complexities of insulin allergy: a case and approach
title The complexities of insulin allergy: a case and approach
title_full The complexities of insulin allergy: a case and approach
title_fullStr The complexities of insulin allergy: a case and approach
title_full_unstemmed The complexities of insulin allergy: a case and approach
title_short The complexities of insulin allergy: a case and approach
title_sort complexities of insulin allergy: a case and approach
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320219/
https://www.ncbi.nlm.nih.gov/pubmed/34325725
http://dx.doi.org/10.1186/s13223-021-00554-1
work_keys_str_mv AT aberumandbabak thecomplexitiesofinsulinallergyacaseandapproach
AT jeimysamira thecomplexitiesofinsulinallergyacaseandapproach
AT aberumandbabak complexitiesofinsulinallergyacaseandapproach
AT jeimysamira complexitiesofinsulinallergyacaseandapproach